Fig. 2From: Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathwayCorrelation between 25 TFs and clinical features in PCa. A Expression of 25 TFs in PCa patients with GS < 8 (n = 285) and GS ≥ 8 (n = 196). B Expression of 25 TFs in PCa patients with T1–T2 stage (n = 186) and T3–T4 stage (n = 288). C Expression of 25 TFs in PCa patients with N0 stage (n = 337) and N1 stage (n = 75). D Expression of 25 TFs in PCa patients with M0 stage (n = 440) and M1 stage (n = 3). (*P < 0.05, **P < 0.01, ***P < 0.001)Back to article page